Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999226 · ClinicalTrials.gov registry record · NA
RENEW-AI: Personalizing Scleroderma Management With an AI Health Coach
A NA study of Scleroderma, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06999226: Completed NA study of Scleroderma, sponsored by University of Michigan.
NCT06999226 is a NA study of Scleroderma that has completed, run by University of Michigan. The registered enrollment target is 20 participants, below the 402-participant average among 23 other Scleroderma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999226, a NA study of Scleroderma, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to explore the use of a large language model (LLM) in providing education and behavioral health coaching for individuals with Systemic Sclerosis (SSc). The goal of the LLM is to help user set or modify behavioral goals, provide education, or emotional support as needed by the participant. The primary outcome for this study is to assess the feasibility and acceptability of using an AI-supported health coaching tool over a four-week period.
Primary Outcome
Engagement is measured through app analytics (It will be reported as the proportion of participants who use the chat feature.)
Conditions Studied
Interventions
- BEHAVIORAL RENEW-AI
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2025-08-01 |
| Phase | NA |
What the finished NCT06999226 record still lists
NCT06999226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 402-participant average among 23 other Scleroderma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 1 intervention - of which RENEW-AI is the first listed.
NCT06999226 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06999226 about?
NCT06999226 is a clinical study titled "RENEW-AI: Personalizing Scleroderma Management With an AI Health Coach". The purpose of this pilot study is to explore the use of a large language model (LLM) in providing education and behavioral health coaching for individuals with Systemic Sclerosis (SSc). The goal of the LLM is to help user set or modify behavioral goals, provide education, or emotional support as ne...
What is the current status of trial NCT06999226?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2025-05-19. Estimated completion is 2025-08-01.
What conditions does trial NCT06999226 study?
This clinical trial studies the following conditions: Scleroderma.
What interventions are being tested in trial NCT06999226?
The interventions under investigation include: RENEW-AI (BEHAVIORAL).
Who is sponsoring clinical trial NCT06999226?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999226 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06999226's enrollment target sits among peer trials
20 21st of 23 higher than 3 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
RECRUITING · NA
-
Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma
COMPLETED · NA
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI